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osting by EAbstract Type 2 diabetes mellitus is a heterogeneous disease of polygenic origin and involves both
defective insulin secretion and peripheral insulin resistance. Studies have shown that post-meal
hyperglycemic spikes are associated with increased cardiovascular mortality in type 2 diabetes. Over
the past decade, a major interest in control of postprandial glucose excursion has emerged and a
plethora of new medications that speciﬁcally target postprandial hyperglycemia were discovered.
Despite the availability of new agents for treatment of type 2 diabetes mellitus, oral sulfonylureas
remain a cornerstone of therapy, because they are relatively inexpensive and are well tolerated.
However, hypoglycemia is a major safety concern with sulfonylureas and it is one major risk factor
requiring hospitalization. Glipizide is a potent, rapid-acting with short duration of action and well
tolerated second-generation sulfonylurea effective in reducing postprandial glucose levels. However,
risk of postprandial hypoglycemia and post-meal glucose excursions, if dose missed before meal; are
always associated with the use of glipizide for treatment of type 2 diabetes mellitus. Since, the site of
absorption of glipizide is from stomach thus dosage forms that are retained in stomach by mucoad-
hesion; would increase absorption, improve drug efﬁciency and decrease dose requirements. Micro-
sphere carrier systems made by using polymer galactomannan having strong mucoadhesive72390321.
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144 P. Gaba et al.properties and easily biodegradable could be an attractive strategy to formulate. The purpose of this
research work is to formulate galactomannan coated mucoadhesive microspheres of glipizide and
systematically evaluate its in vitro characteristics and in vivo performance for sustained glucose low-
ering effect and improvement in diabetic condition as compared to immediate release of glipizide.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Type 2 diabetes mellitus (T2DM) is associated with many
health complications and its epidemic prevalence has taken it
to the forefront, thus making it necessary to discover new
drugs and novel methods for treatment. Once diabetes is estab-
lished, chronic hyperglycemia can exert deleterious effects on
b-cell function known as glucotoxicity (Vincent and Robert-
son, 2008). Postprandial hyperglycemia is a prominent and
early defect in diabetes and characterized by a rapid and large
increase in blood glucose levels, and the possibility that these
postprandial ‘‘hyperglycemic spikes’’ may be relevant to the
pathophysiology of late diabetes complications.
Studies have shown that post-meal hyperglycemia is associ-
ated with increased cardiovascular mortality in T2DM and
have focused the attention of anti-diabetic drug discovery to
limit post-meal glucose excursions. Over the last decade, new
medications that speciﬁcally target postprandial glucose
(PPG) were approved by FDA for treatment of diabetes. These
include insulin analogs (lispro and aspart), insulin secreta-
gogues (repaglinide and nateglinide), a-glucosidase inhibitors
(miglitol and acarbose), injectable amylin analogs and gluca-
gon like peptide receptor agonists (Schrot, 2004). Despite the
availability of new agents for treatment of T2DM, oral sulfo-
nylureas remain a cornerstone of therapy. Sulfonylureas are
appealing in the treatment of T2DM because they are rela-
tively inexpensive and are well tolerated. However, hypoglyce-
mia is a major safety concern with sulfonylureas. Glipizide is a
second-generation sulfonylurea that acutely lowers blood glu-
cose level by stimulating the release of insulin from pancreas
and typically prescribed to treat T2DM. Its short biological
half-life (3.4 ± 0.7 h) necessitates it be administered in 2–3
doses of 2.5–10 mg/day (Sharma et al., 2008). Thus, develop-
ment of controlled-release dosage forms would clearly be
advantageous in terms of decreased dosage requirements thus
increase patient compliance and better control over post-meal
hyperglycemic spikes along with low risk of hypoglycemia.
Microsphere carrier systems made from naturally occurring
mucoadhesive polymers have attracted considerable attention
for several years in sustained drug delivery. Recently, dosage
forms that can precisely control release rate and target drugs
to speciﬁc site have made an enormous impact for formulation
and development of novel drug delivery systems. Microspheres
play an important role in novel drug delivery systems (Woo
et al., 2001; Capan et al., 2003; Gohel and Amin, 1998). They
have varied applications and are prepared using assorted poly-
mers (Vasir et al., 2003). However, the success of these micro-
spheres is limited owing to their short residence time at the site
of absorption. It would, therefore, be advantageous to have
means for providing an intimate contact of the drug delivery
system with absorbing membranes (Ikeda et al., 1992; Nagai
et al., 1984; Illum et al., 1988; Schaefer and Singh, 2000). This
can be achieved by coupling bioadhesion characteristics tomicrospheres and developing mucoadhesive microspheres.
Mucoadhesive microspheres have advantages such as efﬁcient
absorption and enhanced bioavailability of drugs owing to a
high surface-to-volume ratio, much more intimate contact with
mucus layer, and speciﬁc targeting of drugs to absorption site
(Rao and Sharma, 1997; Lehr et al., 1992; Henriksen et al.,
1996; Chowdary and Rao, 2003). Galactomannan gum (guar
gum) is extracted from the seed of the leguminous shrub
Cyamopsis tetragonoloba (Budaveri et al., 1996). It is reverse
polysaccharide consisting of monosaccharide mannose and
galactose units (Desai et al., 2004). It was selected as a polymer
for preparation of mucoadhesive microspheres because of
good mucoadhesive and biodegradable properties. Guar gum
is hydrophilic and swells in cold water, forming viscous colloi-
dal dispersions or sols. The physicochemical and viscoelastic
properties of galactomannan are investigated. The rheological
properties are estimated by using different Rheometer. In the
present study galactomannan coated glipizide microspheres
were prepared and characterized by in vitro systems. In addi-
tion these microspheres were evaluated in vivo for their sus-
tained glucose lowering effect and translation of this effect as
a potential therapeutic utility for treatment of T2DM.2. Materials and methods
2.1. Materials
Glipizide received as a gift sample fromMicro Labs Pondicher-
ry, India. Galactomannan gum, Span 80 and glutaraldehyde
were procured from Central Drug House New Delhi, India.
Tween 80 and carboxy methyl cellulose (CMC) was procured
from Loba Chem Pvt. Ltd., Mumbai. Castor oil LR was pur-
chased from Qualigens Fine Chemicals, Mumbai. Streptozoto-
cin (STZ) and glucose were purchased from Sigma–Aldrich,
USA. All solvents and reagents used were of analytical grade.
2.1.1. Animals
Male Sprague–Dawley (SD) rats 8–10 weeks old and Swiss Al-
bino Mice (SAM), 6–7 weeks old, were used in the present
study. They were housed in standard polypropylene cages with
free access to water and standard chow diet. The rats and mice
were exposed to 12 h light and 12 h dark cycle. The experi-
ments were conducted between 9:00 and 17:00 h.
2.2. Methods
2.2.1. Preparation of galactomannan gum microspheres
Microspheres were prepared using emulsiﬁcation-cross linking
technique (Wong et al., 2002). Varying concentrations of gli-
pizide were prepared in 10 g distilled water containing Tween
80 (1%, w/w) followed by stirring for 30 min on magnetic
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allowed to swell for 2 h. This viscous dispersion was then
poured into 50 g of castor oil containing 1.5 g Span 80 using
a mechanical stirrer at 3000 rpm. After complete mixing,
0.1 ml of concentrated sulfuric acid and 0.75 ml of glutaralde-
hyde were added to the dispersion, followed by stirring at con-
stant speed 3000 rpm for 4 h at 50 C. The microspheres
formed and collected by sedimentation, followed by decanta-
tion of oil, were then washed with several fractions of isopro-
pyl alcohol. The residual glutaraldehyde was removed by the
reaction with sodium bisulﬁte. The microspheres were ﬁltered
and dried for 24 h using vacuum desiccator at room tempera-
ture. The ﬁnal preparation was of free ﬂowing powder of
spherical micron-sized particles.
Similarly different batches of microspheres were prepared
by varying galactomannan gum concentration, speed of stir-
ring and temperature effect, characterized on the basis of their
particle size, shape, surface morphology and encapsulation
efﬁciency (Table 1).
2.2.2. Assay of glipizide
Glipizide was estimated by ultraviolet visible spectrophotomet-
ric method (Shimadzu UV-1700, Japan). Aqueous solutions of
glipizide were prepared in phosphate buffer (pH 7.4) and absor-
bance was measured on UV/Vis spectrophotometer at 275 nm
(The United States Pharmacopoeia, 2003). The method was
validated for linearity, accuracy and precision. The method
obeys Beer’s Law in the concentration range of 5–50 lg/ml.
3. Evaluation of microspheres
3.1. Percentage yield (w/w)
The dried microspheres were weighed and their percentage
yield (w/w) was determined by using following formula
(Ziyaur et al., 2006):
% yield ¼ Amount of dried microspheres recovered
Amount of drugþAmount of polymer3.2. Flow properties of microspheres
3.2.1. Angle of repose
Weighed quantity of microspheres was passed through a fun-
nel ﬁxed on a stand at a speciﬁc height upon graph paper. A
static heap of powder with only gravity acting upon it wasTable 1 Composition of mucoadhesive microsphere formula-
tions of glipizide.
Code Drug
(%, w/w)
Galactomannan
gum (%, w/w)
Temperature
(C)
Stirring speed
(rpm)
F1 1.0 2.0 50 3000
F2 2.0 2.0 50 3000
F3 3.0 2.0 50 3000
F4 2.0 1.0 50 3000
F5 2.0 3.0 50 3000
F6 2.0 2.0 50 2000
F7 2.0 2.0 50 4000
F8 2.0 2.0 40 3000
F9 2.0 2.0 60 3000tending to form a conical mound. The height of the heap (h)
and radius (r) of lower part of cone were measured. The angle
of repose was calculated using formula:
tan h ¼ h=r
Therefore,
h ¼ tan1 h=r
where h= angle of repose, h= height of cone and r= radius
of cone base.
3.2.2. Carr’s index
The simple test evaluated the ﬂowability of a powder by com-
paring the poured density and tapped density of a powder. It
was determined by taking small quantity of microsphere sam-
ples in 10 ml measuring cylinder. The height of the sample was
measured before and after tapping indicates the poured and
tapped density.
Carr’s index was calculated as:
I ¼ Vb  Vt
Vb
 100
where Vb is bulk volume and Vt is tapped volume.
3.2.3. Hausner ratio
Hausner ratio was calculated using formula:
Hausner ratio ¼ qt
qd
where qt is tapped density and qd is bulk density.
3.3. Particle size analysis
Particle size of the microspheres was determined by optical
microscopy using stage micrometer and ocular micrometer (Eu-
gene, 1991).Microspheres were suspended in distilled water and
mounted on a glass slide. A minimum of 200 microspheres per
batch were counted for determination of particle size.
3.4. Shape and surface morphology
The external morphology of microspheres was analyzed by
scanning electron microscope (SEM). For scanning electron
microscopy samples were prepared by lightly sprinkling micro-
sphere powder on a double adhesive tape, which stuck to an
aluminum stub. The stubs were then coated with gold to a
thickness of (150–200 A˚) using a ﬁne coat ion sputter (JEOL,
ﬁne coat ion sputter JFC-1100). The microspheres were exam-
ined under scanning electron microscope (JEOL, JSM-6100
SEM, Japan).
3.5. Encapsulation efﬁciency
Accurately weighed amount (50 mg) of the microsphere for-
mulations were dispersed in 50 ml of phosphate buffer
pH 7.4. The sample was ultrasonicated for three consecutive
periods of 5 min each, with a resting period of 5 min each. It
was left to equilibrate for 24 h at room temperature, and the
suspension was then centrifuged at 3000 rpm for 15 min. The
supernatant was diluted appropriately with phosphate buffer
pH 7.4 and analyzed spectrophotometrically at 275 nm.
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mula (Rahman et al., 2006):
Encapsulation efficiency ¼ Drug entrapped
Theoretical drug content
 1003.6. Equilibrium swelling studies of microspheres
Swelling index was determined by measuring the extent of
swelling of microspheres in phosphate buffer. To ensure com-
plete equilibrium, exactly weighed 100 mg of microspheres
were allowed to swell in simulated intestinal ﬂuid pH 7.4 for
24 h. The excess surface adhered liquid drops were removed
by blotting and swollen microspheres were weighed by using
microbalance. The degree of swelling was then calculated by
the following formula (Soppimath and Aminbhavi, 2002):
Degree of swelling ¼Mo Mt=Mt  100
where Mt = initial weight of microspheres and Mo = weight
of microspheres at equilibrium swelling in the media.
3.7. Mucoadhesion testing by in vitro wash-off test
The mucoadhesive property of microspheres was evaluated by
in vitro adhesion testing method called as wash-off method
(Lehr et al., 1990). A 1 cm piece of rat stomach mucosa was
tied onto a glass slide using thread. About 100 microspheres
were spread on wet, rinsed, tissue specimen, and the prepared
slide was hung onto one of the groves of a USP tablet disinte-
grating test apparatus. The disintegrating test apparatus was
operated such that tissue specimen was given regular up and
down movements in a beaker containing a simulated gastric
ﬂuid (pH 1.2). After 30 min at the end of 1 h, and at hourly
intervals up to 12 h, the machine was stopped and the number
of microspheres still adhering to the tissue was counted. The
results of in vitro wash-off test of batches F1–F9 are given in
Table 2.
3.8. In vitro drug release studies
The in vitro dissolution studies were performed at three differ-
ent pH values: (i) 1.2 pH (simulated gastric ﬂuid) (ii) 6.8 pH
and (iii) 7.4 pH (simulated intestinal ﬂuid). In vitro drug release
studies were carried out using US Pharmacopoeia paddle type-
II dissolution apparatus at 37 ± 0.5 C with constant stirring
rate of 50 rpm. Microspheres equivalent to 10 mg of glipizideTable 2 Physical characteristics of mucoadhesive microspheres of g
Code Particle size (lm) Yield (%) Encapsulation
eﬃciency (%)
Angle of
repose
F1 25.80 ± 0.77 68.66 ± 0.11 69.87 ± 1.08 24.90 ±
F2 17.44 ± 1.08 73.50 ± 0.83 74.62 ± 1.15 17.30 ±
F3 15.50 ± 0.91 70.00 ± 0.44 70.00 ± 1.83 13.90 ±
F4 15.48 ± 1.11 66.00 ± 0.59 64.70 ± 0.98 31.10 ±
F5 25.70 ± 1.27 74.00 ± 1.22 73.08 ± 0.82 27.15 ±
F6 20.50 ± 1.69 63.75 ± 1.76 69.90 ± 1.41 34.17 ±
F7 13.70 ± 0.56 70.20 ± 2.00 68.55 ± 0.28 27.10 ±
F8 21.44 ± 1.08 70.50 ± 0.13 68.87 ± 1.08 22.90 ±
F9 17.50 ± 0.91 68.01 ± 0.44 73.12 ± 1.05 19.30 ±were used for the test. An accurately weighed sample was
responded in dissolution media consisting 900 ml of 0.1 N
(pH 1.2) HCl containing 0.01% sodium lauryl sulphate and
dissolution was done for 2 h. The dissolution medium was then
replaced with pH 7.4 phosphate buffer (900 ml) and drug re-
lease study was carried out for further 3 h. Finally, the disso-
lution medium was replaced with phosphate buffer pH 6.8
(900 ml) and dissolution was continued for a further period
of 24 h as the average residence time for intestine. A sample
volume of 5 ml was withdrawn from each dissolution vessel
at regular intervals and replaced with equal volume of fresh
dissolution medium. The sample was ﬁltered and analyzed
spectrophotometrically at 275 nm. All dissolution studies were
carried out and standard deviation was applied (Hardy et al.,
1987).
3.9. Kinetics modeling
Data obtained from dissolution studies was ﬁtted to various
kinetic equations. The kinetic models were used zero order
equation (Q= Qo  kot) (Saravanam et al., 2004), ﬁrst order
equation (ln Q= ln Qo  k1t) (Panday et al., 2003), Higuchi’s
equation (Q= kht1/2) (Ishikawa et al., 2000) and Korsmeyer–
Peppas equation (Chowdary and Ramesh, 1993), log Qt vs.
log t, where Qt is the cumulative amount of drug release at
time t and Qo is the initial amount of drug present in micro-
spheres. ko is the zero order release rate constant, k1 is the ﬁrst
order release rate constant, and kh is the diffusion rate con-
stant. The coefﬁcient of regression and release rate constant
values for zero, ﬁrst and Higuchi and Korsmeyer–Peppas mod-
els were computed.
3.10. In vivo evaluation
3.10.1. Extended release effect of galactomannan coated
glipizide microspheres on blood glucose lowering in rats
Microspheres of F2 batch were evaluated in vivo in normal,
healthy SD rats for their release effect by measuring their po-
tential to lower blood glucose levels for an extended time per-
iod at a dose equivalent to glipizide. The approval of an animal
ethics committee was obtained before starting the study. Rats
were kept on fasting for overnight. Next day morning rats were
randomized into different groups (N= 4) based on blood glu-
cose from tail vein by using Accu-chek glucometer. At time T0
rats were administered blank microspheres to group 1, galacto-
mannan gum coated glipizide microspheres (eq. to 2 mg/kg oflipizide.
Bulk density
(g/cc)
Taped density
(g/cc)
Degree
of swelling
In vitro wash
oﬀ test (%)
1.02 0.34 ± 0.04 0.41 ± 0.03 0.69 65
0.78 0.57 ± 0.10 0.67 ± 0.04 0.99 82
1.05 0.36 ± 0.03 0.42 ± 0.06 0.96 60
1.55 0.47 ± 0.07 0.54 ± 0.10 1.06 71
0.99 0.14 ± 0.02 0.17 ± 0.01 1.18 77
0.85 0.61 ± 0.07 0.71 ± 0.03 1.11 59
1.11 0.53 ± 0.06 0.62 ± 0.09 1.01 50
1.12 0.44 ± 0.14 0.49 ± 0.13 0.99 61
0.98 0.67 ± 0.10 0.61 ± 0.14 1.19 52
Galactomannan gum coated mucoadhesive microspheres of glipizide for treatment of type 2 147glipizide) to group 2 and glipizide (2 mg/kg) to group 3,
suspended in 0.25% CMC. Glucose (2 g/kg) was administered
orally by gavage simultaneously to all the groups. Blood glu-
cose was measured at T0.5h, T1h and T2h. At time T6h again rats
were administered with glucose (2 g/kg) and blood glucose was
measured at T6.5h, T7h and T8h.
3.10.2. Chronic in vivo activity in diabetic mice
Male Swiss Albino Mice (SAM), 6–7 weeks old, was used in
the present study. Mice were made diabetic by injection of
STZ (150 mg/kg/i.p.). On day 0 STZ induced diabetic swiss
mice were randomized on the basis of fasting blood glucose
(FBG) into three groups (N= 6) and oral glucose tolerance
test (OGTT) was performed. For OGTT, at time T0 mice were
administered with glucose (2 g/kg/p.o.) and blood glucose was
measured at time T0.25h, T0.5h, T1h and T2h using Accu-chek
glucometer after glucose administration. From day 1 mice
were administered with blank microspheres (control group),
glipizide (2 mg/kg) and galactomannan gum coated glipizide
microspheres (eq. to 2 mg/kg of glipizide), suspended in
0.25% CMC for 28 days. Random blood glucose (RBG) was
measured on day 1 and 28 before drug administration. FBG
was measured at day 14 before drug administration and day
29. On day 29 OGTT was carried out and AUC0–2h was calcu-
lated. RBG was measured again one week after cessation of
therapy (day 35). Percent change in FBG (day 0 vs. day 14
and 29; Fig. 5), RBG (day 1 vs. day 28 and 35; Fig. 6) and
AUC for OGT (day 1 vs. day 29; Fig. 7) as compared to vehi-
cle control was calculated and plotted.
3.11. Statistical analysis
Statistical analysis was performed by using SIGMASTAT ver-
sion 3.5 by Systat Software Inc., Richmond, USA. Results
were analyzed by one way analysis of variance (ANOVA) fol-
lowed by post hoc Tuckey’s test. ‘‘p’’ value of less than 0.05
was considered as statistically signiﬁcant.
4. Results and discussion
Cross-linked microspheres of galactomannan gum loaded with
glipizide were successfully prepared by the emulsiﬁcation tech-
nique using castor oil in the external phase. Rigidity of the
microspheres was induced by chemical cross-linking method
utilizing glutaraldehyde as cross-linker. The acidic medium re-
quired for the process of cross-linking was imparted by the addi-
tion of concentrated sulphuric acid. The placebo microspheresFigure 1 (a) Scanning electron microscopy of cross-linked galacto
microscopy of microspheres prepared with 2% galactomannan gum an
1% galactomannan gum.were discrete and fairly spherical in shape while the surface
roughness was slightly increased with the incorporation of the
drug (Fig. 1a). Tween 80 was used for the purpose of wetting
of galactomannan gum. Formulations were also tried without
using Tween 80 and lumps were obtained which were difﬁcult
to suspend in the castor oil. Excellent microspheres were pro-
duced when the process was carried out with 2% galactoman-
nan gum (Fig. 1b) while the shape of the microspheres was
distorted and some of them fused to each other when prepared
with 1% galactomannan gum concentration (Fig. 1c). It may be
due to the presence of higher amount of water, which slowly
evaporated on stirring, causing the particles to come in contact
with each other. The temperature of the system plays a vital role
in the process of formation of microspheres.
Very good microspheres were produced when process was
carried out at 50 C. Microspheres with relatively hard sur-
faces and cracks were produced when the process was per-
formed at 60 C (Fig. 2a). It could be due to rapid
evaporation of water from the dispersed solution of galacto-
mannan gum in castor oil. The drug particles appeared on
the surface of microspheres when they were prepared with
3% drug (Fig. 2b).
Microspheres with optimum shape and size were produced
when agitated at 3000 rpm. With increasing agitation speed,
microspheres with randomly fractured edges were produced
which was due to high shear force of the blades of the agitator.
When the agitation speed was kept below 2000 rpm, the galac-
tomannan gum solution did not disperse evenly and micro-
spheres with irregular geometry were produced and some of
them adhered to the shaft and vessel wall.
Mean particle size of the galactomannan gum microspheres
prepared with 1% of the drug was found to be 25.80 ±
0.77 lm while it was signiﬁcantly decreased to 15.50 ±
0.91 lm when drug concentration was increased to 3% (Table
2). Particle size was found to be increasing with increasing
galactomannan gum concentration. Mean particle size was
found to be 15.48 ± 1.11 lm with microspheres having 1%
galactomannan gum while it was signiﬁcantly increased to
17.44 ± 1.08 lm with 2% galactomannan gum concentration.
The size of the microspheres is controlled by the size of the dis-
persed droplets of galactomannan gum in castor oil. When the
concentration of the galactomannan gum in the formulation
was increased, there was increment in the size of dispersed
droplets that resulted in the formation of microspheres having
bigger particle size.
In the present investigation 2% galactomannan gum con-
centration was found to be optimal, ensuring the optimal size
of microspheres. The average particle size of microspheresmannan gum microspheres bearing drug, (b) scanning electron
d (c) scanning electron microscopy of microspheres prepared with
Figure 2 (a) Scanning electron microscopy of microspheres prepared at 60 C and (b) scanning electron microscopy of microspheres
prepared with 3% drug.
148 P. Gaba et al.increased with increasing polymer concentration, since at high-
er concentrations the polymer solution dispersed into larger
droplets. At concentrations lower than optimum the solution
became less viscous and dispersed into numerous ﬁne droplets
that easily coalesced, resulting in larger microspheres. The
mean particle size of microspheres decreased from
20.50 ± 1.69 to 13.70 ± 0.56 lm with increasing mixer rota-
tional speed from 2000 to 4000 rpm. Results revealed that
the average diameter of microspheres was controlled by rota-
tional speed. The ultimate mean diameter of microspheres
was determined by the size of dispersion of the polymer solu-
tion, which decreased with increasing mixer rotational speed.
Results also suggested that there was a mixing rate limit for
a particular polymer concentration. A higher mixing rate did
not further reduce the mean diameter. The mixing speed of
3000 rpm was found to be optimal for galactomannan gum
microspheres. The effect of stirring time at a particular rota-
tional speed was also observed, and it was recorded that stir-
ring time inﬂuenced the shape as well as the size distribution
of microspheres, possibly because of variable shear force expe-
rienced by the particulate system. A mixing time of 4 h was
found to be optimal.
The % age yield values for galactomannan gum micro-
spheres were studied. In case of galactomannan gum it was ob-
served that with increase in galactomannan gum concentration
the % age yield also increases. With stirring speed from 2000
to 4000 rpm, the % age yield values were improved from
63.75 to 70.20%. Encapsulation efﬁciency of the formulation
was found to be 69.87 ± 1.08% with 1% drug concentration
and it increased to 74.62 ± 1.15% when the drug concentra-
tion was increased to 2% (Table 2). Encapsulation efﬁciency
reduced to 70.00 ± 1.83% when the drug concentration was
increased to 3% which could due to the limited aqueous solu-
bility of the drug and that is endorsed from the presence of
drug particles on the surface of microspheres prepared 3%
of drug concentration.
It is evident from the table that increase in galactomannan
gum concentration led to an increase in the encapsulation efﬁ-
ciency and this is because of increase in dispersion of the drug
in the dispersed phase but further increase in the galactoman-
nan gum concentration led to increase in the viscosity of the
medium resulting in improper dispersion of galactomannan
gum in the dispersion medium resulting in decrease in the
encapsulation efﬁciency. So the galactomannan gum concen-
tration should be optimum to avoid higher viscosity and to
get better encapsulation efﬁciency.Further, it was observed that stirring speed did not have
signiﬁcant effect on encapsulation efﬁciency (Chourasia and
Jain, 2004). The galactomannan gum microspheres were sub-
jected to in vitro drug release rate studies in simulated gastric
ﬂuid (SGF) (pH 1.2) for 2 h and simulated intestinal ﬂuid
(SIF) (pH 7.4) for 3 h in order to investigate the capability
of the formulation to withstand the physiological environment
of the stomach and small intestine. The amount of glipizide re-
leased during 5 h studies was found to be 15.20 ± 0.71%,
which attests the ability of the galactomannan gum to remain
intact in the physiological environment of stomach and small
intestine. The little amount of the drug, which is released dur-
ing 5 h release rate studies, is due to the presence of un-en-
trapped drug on the surface of the microspheres. It is a well
established fact that as the galactomannan gum come in con-
tact with the dissolution medium it creates viscous gel layer
around it which controls the release of the entrapped drug.
The initial release of the drug present on the surface was higher
during the 2 h study, which could be due to the fact that there
was no viscous gel layer around the particles and it might have
formed after 2 or 3 h which controlled the further release of
drug. These results are concordant with the results of that have
used matrix and compression coated tablets of galactomannan
gum, respectively, for colon targeted delivery (Rama Prasad
et al., 1998; Krishnaiah et al., 2002). After 5 h of testing in
0.1 M HCl and pH 6.8 Sorensen’s phosphate buffer,
20.96 ± 0.58% of the drug was released in case of matrix tab-
lets, whereas in case of compression coated tablets only 2.5–
4% of the drug was released which was due to the strong
shielding effect of compression coat of galactomannan gum.
Results showed that maximum drug was release in case of
F2 because of high encapsulation efﬁciency and optimum con-
centration of all the variables from 5.75% (pH 1.2), 16.08%
(pH 7.4) and 86.20% (pH 6.8) at the end of 24 h (Fig. 3a).
In case of batches with varying polymer concentrations,
batch F4 released 5.91% of drug in pH 1.2 which was higher
than all the batches with varying polymer concentrations. It
may be due to lower galactomannan gum content. It was a well
established fact that as the galactomannan gum comes in con-
tact with the dissolution medium it creates viscous gel layer
around it which controls the release of the entrapped drug
(Gohel et al., 1997).
In case of F5 galactomannan gum concentration was too
high that it did not release adequate amount of drug till the
end of study. It may be due to highest encapsulation efﬁciency
and having optimum concentration of all the variables leading
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Figure 3 (a) Comparison of percentage drug release from varying drug concentration batches F1, F2 and F3. (b) Comparison of
percentage drug release from varying polymer concentration batches F2, F4 and F5. (c) Comparison of percentage drug release from
varying stirring speed batches F2, F6 and F7. (d) Comparison of percentage drug release from varying temperature batches F2, F8 and F9.
Table 3 In vitro release kinetics model of galactomannan gum microspheres.
Code Zero order equation First order equation Higuchi equation Korsmeyer–Peppas equation
R2 K R2 K R2 K Slope (n) R2 Drug transport mechanism
F1 0.9778 3.8196 0.9651 0.0723 0.9182 18.943 1.2343 0.995 Super Case-II transport
F2 0.9937 3.8458 0.9402 0.0764 0.9164 18.898 1.3067 0.991 Super Case-II transport
F3 0.9897 3.6339 0.9742 0.0672 0.9290 18.015 1.1492 0.990 Super Case-II transport
F4 0.9861 3.559 0.9629 0.0658 0.9370 17.754 1.238 0.981 Super Case-II transport
F5 0.9897 3.3633 0.9638 0.0587 0.9229 16.619 1.234 0.980 Super Case-II transport
F6 0.9895 3.5774 0.9803 0.0649 0.9347 17.790 1.1721 0.997 Super Case-II transport
F7 0.9932 3.3050 0.9589 0.0568 0.9213 16.287 1.2047 0.983 Super Case-II transport
F8 0.9905 3.5232 0.9683 0.0631 0.9303 17.471 1.3528 0.982 Super Case-II transport
F9 0.981 3.5569 0.9832 0.0628 0.9318 17.737 1.3158 0.993 Super Case-II transport
Galactomannan gum coated mucoadhesive microspheres of glipizide for treatment of type 2 149to 5.21% (pH 1.2), 17.32% (pH 7.4) and 77.40% (pH 6.8) at
the end of 24 h (Fig. 3b). Further, it was observed that the tem-
perature change (Fig. 3c) and stirring speed (Fig. 3d) did not
have signiﬁcant effect in drug release. Hence batch F2 has been
chosen as an optimum polymer concentration as it released
maximum 86.20% of drug till the end of study.
Native galactomannan gum swells 100–120 folds in gastric
and intestinal ﬂuids. As a result of cross-linking with glutar-
aldehyde the overall swelling of polymer decreased signiﬁ-
cantly. Cross-linking interferes with free access of water to
the galactomannan gum hydroxyl group, which in turn re-
duces the swelling properties of the cross-linked polymer.The cross-linking of the modiﬁed galactomannan gum for-
mulation depended on the glutaraldehyde concentration,
but the optimal concentration of the cross-linking agent
was a compromise between swellability and in vitro digestion
of microspheres.
The data from in vitro study was ﬁtted to various kinetic
models to determine the kinetics of drug release. The main
models are zero order, ﬁrst order, Higuchi and Korsmeyer to
understand the drug release from the microspheres. The coef-
ﬁcients of regression and release rate constant values were
computed. However drug release was also found to be very
close to zero order kinetics, indicated that the concentration
150 P. Gaba et al.was nearly independent of drug release. The corresponding
plot (log cumulative percent drug release vs time) for Kors-
meyer–Peppas equation indicated a good linearity. Mechanism
of drug release from formulations was determined by
Korsmeyer–Peppas equation where exponent n indicated
mechanism of drug release. It indicated coupling of diffusion
and erosion mechanism called Super Case-II transport
(Table 3).
Based on these results formulations F2 were considered as
best batch for sustained release of glipizide. Thus optimized
batch F2 was studied further for its in vivo potential to con-
trol blood glucose for an extended time period after oral
administration in lean SD rats. It was observed that single
dose galactomannan coated glipizide microspheres exhibited
reduction in blood glucose for a longer period as compared
to immediate release formulation of glipizide (Fig. 4).
To probe the potential therapeutic utility and to translate
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glipizide group.in diabetic conditions; anti-diabetic effect of galactomannan
coated mucoadhesive microspheres were tested in STZ in-
duced diabetic Swiss albino mice. Mice were administered
with vehicle (0.25% CMC), galactomannan coated glipizide
microspheres and glipizide for 28 days. In this study sus-
tained release microspheres of glipizide exhibited signiﬁcant
improvement in various diabetic parameters like FBG
(Fig. 5), RBG (Fig. 6) and OGTT (Fig. 7) as compared to
immediate release formulation of glipizide. To exclude the
possibility that anti-diabetic effect (reduction in RBG at
day 28, FBG and OGT at day 29) of galactomannan coated
glipizide microspheres may be because of sustained release of
glipizide, RBG was measured 1 week post-cessation of ther-
apy. It was observed that the anti-diabetic effect of glipizide
microspheres extended beyond the period of treatment
(Fig. 6). This clearly indicates the potential therapeutic utility
of mucoadhesive extended release formulation of glipizide
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Sustained drug delivery systems are widely useful to provide
constant and sustained therapeutic drug levels. These systems
provide protection of drug in the hostile environment of upper
gastrointestinal track, avoid ﬁrst pass effects, increase patient
compliance and release the drug at speciﬁc site. In present
study, anti-diabetic drug glipizide loaded mucoadhesive micro-
spheres were prepared by using polymer namely galactoman-
nan gum as drug carries. Cross-linked microspheres of
galactomannan gum loaded with drug were successfully pre-
pared by the emulsiﬁcation technique. The prepared micro-
spheres were found to be rough; smooth some of them were
spherical. Based on these results formulation F2 was consid-
ered the best batch for sustained/prolonged release of glipizide.
From this study it is concluded that release of glipizide drug
was slow and extended over a longer period of time depending
upon the composition of polymers and drug. In this study drug
release was diffusion controlled and followed zero order ki-
netic. In vivo evaluation carried out using SD rats and diabetic
Swiss albino mice showed sustained glucose lowering effect of
glipizide microspheres and improvement in various diabetic
parameters as compared to immediate release formulation ofglipizide. Though the mechanism underlying this was not
determined, however, potential explanations may include that
better control of blood glucose may lead to reversal in gluco-
toxicity. Further mechanistic studies are required to conﬁrm
this suggestion.
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